Karen K Giuliano1, Dian Baker2, Barbara Quinn3. 1. Northeastern University, Boston, MA; Department of Nursing, Hallmark Health, Medford, MA; Sage Products, Stryker Medical, Cary, IL. Electronic address: kkgiuliano96@gmail.com. 2. School of Nursing, California State University, Sacramento, CA. 3. Department of Nursing, Sutter Medical Center, Sacramento, CA.
Abstract
BACKGROUND: Nonventilator hospital-acquired pneumonia (NV-HAP) is among the most common hospital-acquired infections. The purpose of our study was to quantify the incidence and influence of NV-HAP in the United States using a national dataset. METHODS: The 2012 US National Inpatient Sample dataset was used to compare an NV-HAP group to 4 additional group cohorts: pneumonia on admission, general hospital admissions, matched on mortality and disease severity, and ventilator-associated pneumonia (VAP). The main outcome was NV-HAP incidence. The secondary outcome was to compare hospital length of stay, total hospital charges, and mortality between the NV-HAP group and the 4 additional group cohorts. RESULTS: The overall incidence of NV-HAP was 1.6%, which represents a rate of 3.63 per 1,000 patient-days. NV-HAP was associated with increased total hospital charges, a longer hospital length of stay, and greater likelihood of death in comparison to all groups except patients with VAP. CONCLUSION: NV-HAP is an underappreciated and serious patient safety issue, resulting in significant increases in cost, length of stay, and mortality. Efforts toward prevention of NV-HAP should be raised to the same level of concern as VAP prevention.
BACKGROUND: Nonventilator hospital-acquired pneumonia (NV-HAP) is among the most common hospital-acquired infections. The purpose of our study was to quantify the incidence and influence of NV-HAP in the United States using a national dataset. METHODS: The 2012 US National Inpatient Sample dataset was used to compare an NV-HAP group to 4 additional group cohorts: pneumonia on admission, general hospital admissions, matched on mortality and disease severity, and ventilator-associated pneumonia (VAP). The main outcome was NV-HAP incidence. The secondary outcome was to compare hospital length of stay, total hospital charges, and mortality between the NV-HAP group and the 4 additional group cohorts. RESULTS: The overall incidence of NV-HAP was 1.6%, which represents a rate of 3.63 per 1,000 patient-days. NV-HAP was associated with increased total hospital charges, a longer hospital length of stay, and greater likelihood of death in comparison to all groups except patients with VAP. CONCLUSION: NV-HAP is an underappreciated and serious patient safety issue, resulting in significant increases in cost, length of stay, and mortality. Efforts toward prevention of NV-HAP should be raised to the same level of concern as VAP prevention.
Authors: Barbara Ebersole; Miriam Lango; John Ridge; Elizabeth Handorf; Jeffrey Farma; Sarah Clark; Nausheen Jamal Journal: Otolaryngol Head Neck Surg Date: 2019-12-03 Impact factor: 3.497
Authors: Paula D Strassle; Emily E Sickbert-Bennett; Michael Klompas; Jennifer L Lund; Paul W Stewart; Ashley H Marx; Lauren M DiBiase; David J Weber Journal: Infect Control Hosp Epidemiol Date: 2019-10-29 Impact factor: 3.254
Authors: Stephen P Bergin; Adrian Coles; Sara B Calvert; John Farley; John H Powers; Marcus J Zervos; Matthew Sims; Marin H Kollef; Michael J Durkin; Badih A Kabchi; Helen K Donnelly; Ana Cecilia Bardossy; Claire Greenshields; Daniel Rubin; Jie-Lena Sun; Karen Chiswell; Jonas Santiago; Peidi Gu; Pamela Tenaerts; Vance G Fowler; Thomas L Holland Journal: Chest Date: 2020-06-29 Impact factor: 9.410
Authors: Muhammad Zubair Khan; Ashwani Gupta; Jordesha Hodge; Kirtenkumar Patel; Krunalkumar Patel; Muhammad Samsoor Zarak; Sona Franklin; Harsh Patel; Shruti Jesani; Sejal Savani; Vraj Shah; Vincent M Figueredo; Arvind R Cavale; Steven Kutalek Journal: J Arrhythm Date: 2021-07-07